The ESMO-EANO clinical practice guidelines for neurological and vascular complications of primary and secondary brain tumours: a valuable tool for clinicians [0.03%]
欧洲神经肿瘤学会和欧洲肿瘤内科学会合作制定的原发性和继发性脑肿瘤所致神经系统和血管并发症临床实践指南：实用的临床工具
J M Sepúlveda-Sánchez,A Pérez-Núñez
J M Sepúlveda-Sánchez
Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study [0.03%]
一项关于科替帕胺联合阿特朱单抗治疗BRAF V600阴性黑色素瘤的III期随机临床研究（IMspire170）的主要结果公布
H Gogas,B Dréno,J Larkin et al.
H Gogas et al.
Background: Emerging data suggest that the combination of MEK inhibitors and immunotherapeutic agents may result in improved efficacy in melanoma. We evaluated whether combining MEK inhibition and immune checkpoint inhibi...
Effectiveness of rituximab in treating immune-checkpoint-inhibitor-induced immune-related adverse events: results of a systematic review [0.03%]
利妥昔单抗治疗免疫检查点抑制剂相关免疫性不良反应的疗效：系统评价结果
S N Deftereos,D Georgonikou
S N Deftereos
A Matikas,T Foukakis
A Matikas
Mutation clearance and complete radiologic resolution of immunotherapy relapsed metastatic melanoma after treatment with nivolumab and olaparib in a patient with homologous recombinant deficiency: any role for PARP inhibitors and checkpoint blockade? [0.03%]
nivolumab和olaparib治疗同源重组缺陷的免疫疗法复发转移性黑色素瘤后病灶完全缓解和超进展型肿瘤消退：PARP抑制剂和免疫检查点阻断的作用？
K Khaddour,M Ansstas,J Visconti et al.
K Khaddour et al.
The effect of age on the acquisition and selection of cancer driver mutations in sun-exposed normal skin [0.03%]
年龄对曝光于阳光的正常皮肤中获得和选择癌驱动突变的影响
B Hernando,M Dietzen,G Parra et al.
B Hernando et al.
Background: The accumulation of somatic mutations contributes to ageing and cancer. Sunlight is the principal aetiological factor associated with skin cancer development. However, genetic and phenotypic factors also contr...
Immunotherapy for early breast cancer: too soon, too superficial, or just right? [0.03%]
早期乳腺癌的免疫治疗：为时过早、浅尝辄止还是恰到好处？
M A Franzoi,E Romano,M Piccart
M A Franzoi
Immunotherapy emerged as a new treatment modality for breast cancer, and its use is approved in combination with chemotherapy for first-line therapy in metastatic triple-negative breast cancer overexpressing PD-L1. As immune checkpoint inhi...
Revisiting anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy [0.03%]
再次探讨抗CTLA-4抗体与PD-1阻滞剂联合用于癌症免疫治疗
M Sznol,I Melero
M Sznol
Key role for liquid biopsy in the elimination of breast cancer surgery following neoadjuvant therapy [0.03%]
液体活检在新辅助治疗后乳腺癌手术消除中的关键作用
A Grinshpun,J Moss,B Uziely
A Grinshpun